Ono Pharmaceutical (4528) Q3 2026 earnings summary

Executive summary

• Achieved record-high third-quarter sales revenue of ¥397.0 billion, up 6.0% year-over-year, driven by increased overseas sales, higher royalty revenue, and expanded product portfolio, despite domestic OPDIVO sales decline due to competition.

• Core operating profit rose 19.1% year-over-year to ¥116.3 billion, and core profit for the period increased 17.6% to ¥90.0 billion.

• Profit attributable to owners (IFRS basis) was ¥68.9 billion, up 21.8% year-over-year.

• Expenses increased from the inclusion of Deciphera Pharmaceuticals for nine months versus six months last year, but profit growth outpaced these costs.

Financial highlights

• Sales revenue: ¥397.0 billion (+¥22.5 billion, +6.0% YoY); highest Q3 sales on record.

• Core operating profit: ¥116.3 billion (+¥18.6 billion, +19.1% YoY).

• Core profit for the period: ¥90.0 billion (+¥13.5 billion, +17.6% YoY).

• Operating profit (IFRS): ¥88.3 billion (+24.8% YoY); profit before tax: ¥89.4 billion (+24.1% YoY).

• Basic earnings per share (IFRS): ¥146.75, up from ¥120.49 YoY.

Outlook and guidance

• FY2025 full-year revenue forecast at ¥490.0 billion (+0.6% YoY); core profit for the period forecast at ¥91.0 billion (+0.7% YoY).

• Operating profit projected at ¥85.0 billion (+42.3% YoY); profit attributable to owners at ¥67.0 billion (+33.9% YoY).

• Growth expected from QINLOCK, ROMVIMZA, and overseas royalty revenue, offsetting domestic declines from generic competition.

• No change to previously announced consolidated financial forecasts.